Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer

BACKGROUND: To determine the maximal tolerated dose of erlotinib when added to 5-fluorouracil (5-FU) chemoradiation and bevacizumab and safety and efficacy of this combination in patients with locally advanced rectal cancer. PATIENTS AND METHODS: Patients with Magnetic resonance imaging (MRI) or ult...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ann Oncol
Glavni autori: Blaszkowsky, L. S., Ryan, D. P., Szymonifka, J., Borger, D. R., Zhu, A. X., Clark, J. W., Kwak, E. L., Mamon, H. J., Allen, J. N., Vasudev, E., Shellito, P. C., Cusack, J. C., Berger, D. L., Hong, T. S.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2014
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4271130/
https://ncbi.nlm.nih.gov/pubmed/24356623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt516
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items